Objectives: We evaluated SOX10 (SRY-related HMG-box 10) in differentiating acinic cell carcinoma (AciCC) from other salivary gland neoplasms with oncocytic features on fine-needle aspiration cell blocks (FNA CB) and compared its performance to DOG1 (discovered on gastrointestinal stromal tumor 1). Material and Methods: 35 FNA CB of oncocytic salivary gland neoplasms, i.e. 13 cases of AciCC, 16 of Warthin tumor (WT), 3 of mucoepidermoid carcinoma (MEC) and 3 of oncocytoma (ONC), and 75 salivary gland resections, i.e. 26 AciCC, 7 WT, 36 MEC, 3 ONC, 2 mammary analog secretory carcinomas (MASC) and 1 papillary cystadenoma were stained for SOX10 and DOG1. Results: None of the benign oncocytic neoplasms were immunoreactive for SOX10 on CB or resection, similar to DOG1. On CB, 61.5 and 77% of AciCC were positive for SOX10 and DOG1, respectively. All surgically resected AciCC cases were positive for SOX10 and DOG1; other malignant oncocytic lesions such as MEC and MASC demonstrated variable SOX10 and DOG1 staining. Conclusion: The use of SOX10 may increase the diagnostic accuracy of oncocytic lesions on FNA. In this context, SOX10 is equivalent to DOG1 in ruling out benign lesions such as WT and ONC; however, negative results for SOX10 as well as DOG1 do not favor a benign diagnosis since MEC is often negative for both markers.

Keywords:
Acinic cell carcinoma, Immunohistochemistry, SOX10, Salivary gland neoplasms, Aspiration cytology
1.
Ellis GL: Benign epithelial neoplasms; in: Tumors of the Salivary Glands, series 4, fascicle 9. Washington, American Registry of Pathology/Armed Forces Institute of Pathology, 2008, pp 96-100.
2.
Thompson LDR: Acinic cell carcinoma; in: Thompson LDR, Wenig BM (eds): Diagnostic Pathology, Head and Neck. Altona, AMIRSYS Inc., 2011, pp 82-85.
3.
Tyagi R, Dey P: Diagnostic problems of salivary gland tumors. Diagn Cytopathol 2015;43:495-509.
4.
Ihrler S, Blasenbreu-Vogt S, Sendelhofert A, et al: Differential diagnosis of salivary acinic cell carcinoma and adenocarcinoma (NOS). A comparison of (immuno-) histochemical markers. Pathol Res Pract 2002;198:777-783.
5.
Hellquist H, Skalova A: Oncocytoma; in: Histopathology of the Salivary Glands. Berlin, Springer, 2014, p 151.
6.
Nagao T, Sato E, Inoue R, et al: Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem 2012;45:269-282.
7.
Kelsh RN: Sorting out SOX10 functions in neural crest development. Bioessays 2006;28:788-798.
8.
Nonaka D, Chiriborga L, Rubin BP: SOX10: a pan-Schwannian and melanocytic marker. Am J Surg Pathol 2008;32:1291-1298.
9.
Tacha D, Weimin Q, Seong R: A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. Arch Pathol Lab Med 2015;139:530-536.
10.
Ohtomo R, Mori T, Shibata S, et al: SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol 2013;26:1041-1050.
11.
Ivanov SV, Panaccione A, Nonaka D, et al: Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer 2013;109:444-451.
12.
Zhu S, Schuerch C, Hunt J: Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med 2015;139:55-66.
13.
Schmitt AC, McCormick R, Cohen C, et al: DOG1, p63, and S100 protein: a novel immunohistochemical panel in the differential diagnosis of oncocytic salivary gland neoplasms in fine-needle aspiration cell blocks. J Am Soc Cytopathol 2014;6:303-308.
14.
Chenevert J, Duvvuri U, Chiosea S, et al: DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol 2012;25:919-929.
15.
Hemminger J, Iwenofu OH: Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms. Histopathology 2012;61:170-177.
16.
Urano M, Nagao T, Satoru M, et al: Characterization of mammary analog secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol 2015;46:94-103.
17.
Lin F: Evolving practices of diagnostic immunohistochemistry. Arch Pathol Lab Med 2014;138:1561-1563.
18.
Ferringer T: Immunohistochemistry in dermatopathology. Arch Pathol Lab Med 2015;139:83-105.
19.
Jain D, Mathur SR, Sharma MC, et al: Cytomorphology of sebaceous carcinoma with analysis of p40 antibody expression. Diagn Cytopathol 2015;6:456-461.
20.
Montalli VA, Martinez E, Tincani A, et al: Tubular variant of basal cell adenoma shares immunophenotypical features with normal intercalated ducts and is closely related to intercalated duct lesions of salivary glands. Histopathology 2014;64:880-889.
21.
Naujoukas A, Charli-Joseph Y, Ruben BS, et al: SOX-10 expression in cutaneous myoepitheliomas and mixed tumors. J Cutan Pathol 2014;41:353-363.
22.
Pinto A, Nose V, Rojas C: Searching for mammary analog secretory carcinoma of salivary glands among its mimics. Mod Pathol 2014;27:30-37.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.